BR112012000569A2 - ácido benzóico, derivados de ácido benzóico e conjugados de ácido heteroaril carboxílico de hidrocodona, pró-farmacos, métodos de produção e uso destes - Google Patents

ácido benzóico, derivados de ácido benzóico e conjugados de ácido heteroaril carboxílico de hidrocodona, pró-farmacos, métodos de produção e uso destes

Info

Publication number
BR112012000569A2
BR112012000569A2 BR112012000569A BR112012000569A BR112012000569A2 BR 112012000569 A2 BR112012000569 A2 BR 112012000569A2 BR 112012000569 A BR112012000569 A BR 112012000569A BR 112012000569 A BR112012000569 A BR 112012000569A BR 112012000569 A2 BR112012000569 A2 BR 112012000569A2
Authority
BR
Brazil
Prior art keywords
benzoic acid
hydrocodone
prodrugs
production
methods
Prior art date
Application number
BR112012000569A
Other languages
English (en)
Other versions
BR112012000569B1 (pt
BR112012000569B8 (pt
Inventor
Andrea K Martin
Bindu Bera
Christal Mickle
Guochen Chi
Jaroslaw Kanski
Sven Guenther
Travis Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43411452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012000569(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of BR112012000569A2 publication Critical patent/BR112012000569A2/pt
Publication of BR112012000569B1 publication Critical patent/BR112012000569B1/pt
Publication of BR112012000569B8 publication Critical patent/BR112012000569B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112012000569A 2009-07-02 2010-07-01 composição compreendendo um conjugado de benzoato-hidrocodona (bz-hc) e composições para administração oral e intravenosa compreendendo o mesmo BR112012000569B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22271809P 2009-07-02 2009-07-02
US61/222,718 2009-07-02
PCT/US2010/040775 WO2011002991A1 (en) 2009-07-02 2010-07-01 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof

Publications (3)

Publication Number Publication Date
BR112012000569A2 true BR112012000569A2 (pt) 2015-09-15
BR112012000569B1 BR112012000569B1 (pt) 2021-02-02
BR112012000569B8 BR112012000569B8 (pt) 2021-05-25

Family

ID=43411452

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000569A BR112012000569B8 (pt) 2009-07-02 2010-07-01 composição compreendendo um conjugado de benzoato-hidrocodona (bz-hc) e composições para administração oral e intravenosa compreendendo o mesmo

Country Status (21)

Country Link
US (14) US8759368B2 (pt)
EP (2) EP2448407B1 (pt)
JP (1) JP5442862B2 (pt)
KR (5) KR101655972B1 (pt)
CN (1) CN102480959B (pt)
AU (1) AU2010266205B2 (pt)
BR (1) BR112012000569B8 (pt)
CA (1) CA2766388C (pt)
CL (1) CL2011003347A1 (pt)
CO (1) CO6480991A2 (pt)
CR (1) CR20110688A (pt)
CU (1) CU24128B1 (pt)
IL (2) IL217096A (pt)
MX (1) MX2012000128A (pt)
MY (1) MY153046A (pt)
NZ (1) NZ597235A (pt)
RU (1) RU2505541C2 (pt)
SG (1) SG177445A1 (pt)
UA (1) UA102916C2 (pt)
WO (1) WO2011002991A1 (pt)
ZA (2) ZA201109438B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US8871780B2 (en) * 2009-07-02 2014-10-28 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
SG11201401856VA (en) * 2011-10-26 2014-05-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
KR101454515B1 (ko) * 2012-12-04 2014-10-23 바이오스펙트럼 주식회사 베라트릭 산 또는 이의 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 피부상태 개선용 조성물
WO2014138740A1 (en) 2013-03-08 2014-09-12 Johnson Matthey Public Limited Company Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
EP3114601B1 (en) * 2014-03-07 2020-01-08 British Telecommunications public limited company Access control for a resource
WO2016064914A1 (en) 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
RU2683317C2 (ru) * 2014-11-25 2019-03-28 Кемфарм, Инк. Конъюгаты оксикодона с бензойной кислотой, производными бензойной кислоты и гетероарилкарбоновой кислотой
RU2683274C2 (ru) 2014-12-02 2019-03-27 Кемфарм, Инк. Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты и оксиморфона, их пролекарства, способы получения и применение
KR20160097867A (ko) * 2015-02-10 2016-08-18 삼성전자주식회사 영상 표시 장치 및 영상 표시 방법
KR101669887B1 (ko) * 2015-03-05 2016-10-28 부산대학교 산학협력단 벤조인산을 유효성분으로 포함하는 임신 촉진용 조성물
US10226456B2 (en) 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US10449190B2 (en) * 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
AU2016332071B2 (en) 2015-10-01 2019-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
KR101800834B1 (ko) 2016-07-20 2017-12-21 중앙대학교 산학협력단 아나카딕산을 유효성분으로 하는 배뇨 장애 예방 및 치료용 조성물
US10406153B2 (en) 2016-08-31 2019-09-10 Noramco, Inc. Process for the preparation of benzhydrocodone hydrochloride
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTIPLE SUBUNITY OPIOID PRODRUGS WITH RESISTANCE TO OVERDOSE AND ABUSE
WO2018191477A1 (en) * 2017-04-14 2018-10-18 Kempharm, Inc. Dextrorphan prodrugs and processes for making and using them
WO2018191474A1 (en) * 2017-04-14 2018-10-18 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them
US11234975B2 (en) 2017-04-14 2022-02-01 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them
AU2019224127B2 (en) * 2018-02-23 2021-12-09 Rhodes Technologies Novel opioid compounds and uses thereof
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
AU2020397821B2 (en) * 2019-12-02 2024-07-25 Academia Sinica PDIA4 inhibitors and use thereof for inhibiting ß-cell pathogenesis and treating diabetes

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB320749A (pt)
US1731152A (en) * 1925-10-27 1929-10-08 Firm C H Boehringer Sohn Process for the manufacture of derivatives of dihydrocodeinone or its substitution products
AT229496B (de) 1961-03-08 1963-09-25 Lannacher Heilmittel Verfahren zur Darstellung des neuen Nicotinsäureesters des Dihydrohydroxycodeinons
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
GB2307833B (en) 1995-12-01 2000-06-07 Geco As A data compression method and apparatus for seismic data
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
US7091040B1 (en) * 1999-01-04 2006-08-15 Innovata Plc P450/acetaminophen genetically directed enzyme prodrug therapy (GDEPT)
MXPA02007252A (es) * 2000-01-28 2003-01-29 Rohm & Haas Compuestos farmaceuticos con propiedades mejoradas.
JP4814486B2 (ja) 2001-06-05 2011-11-16 シヴィダ・インコーポレイテッド 持続放出性鎮痛性化合物
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
KR100822498B1 (ko) * 2002-02-22 2008-04-16 샤이어 엘엘씨 규제된 물질의 남용을 방지하기 위한 새로운 서방성 약학화합물
US20040058946A1 (en) 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
JP2006520392A (ja) 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
EP1782834A3 (en) 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
EA008864B1 (ru) 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
CA2541371C (en) 2003-10-03 2014-12-16 Atul M. Mehta Extended release formulations of opioids and method of use thereof
US20050203115A1 (en) 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
PT1751087E (pt) 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
US7348430B2 (en) 2005-01-21 2008-03-25 Acura Pharmaceuticals, Inc. Production of opioid analgesics
EP2007762A2 (en) 2006-04-10 2008-12-31 Shire LLC Mono and di-substituted oxycodone compounds and compositions
MX2008014794A (es) * 2006-05-26 2009-04-08 Pharmacofore Inc Liberacion controlada de opioides fenolicos.
US20080090771A1 (en) * 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
CA2666582C (en) * 2006-10-20 2014-09-09 Mcneil-Ppc, Inc. Acetaminophen / ibuprofen combinations
WO2009079013A1 (en) * 2007-12-17 2009-06-25 Mallinckrodt Inc. Processes for the production of (+)-'nal' morphinan compounds
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US8871780B2 (en) 2009-07-02 2014-10-28 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof
US8623888B2 (en) * 2009-07-15 2014-01-07 Mallinckrodt Llc 3-oxy-hydromorphone derivatives
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
SG11201401856VA (en) 2011-10-26 2014-05-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
RU2683317C2 (ru) 2014-11-25 2019-03-28 Кемфарм, Инк. Конъюгаты оксикодона с бензойной кислотой, производными бензойной кислоты и гетероарилкарбоновой кислотой

Also Published As

Publication number Publication date
US10351573B2 (en) 2019-07-16
CA2766388C (en) 2014-05-27
RU2012103476A (ru) 2013-08-10
US20150335759A1 (en) 2015-11-26
CU20110246A7 (es) 2012-04-15
KR102038260B1 (ko) 2019-10-29
KR20180081176A (ko) 2018-07-13
EP2448407A1 (en) 2012-05-09
US20170143696A1 (en) 2017-05-25
US8461137B2 (en) 2013-06-11
US20130252994A1 (en) 2013-09-26
IL217096A0 (en) 2012-02-29
EP2448407B1 (en) 2019-09-25
US20160193204A1 (en) 2016-07-07
KR101971223B1 (ko) 2019-04-23
CN102480959A (zh) 2012-05-30
KR20170124638A (ko) 2017-11-10
BR112012000569B1 (pt) 2021-02-02
EP2448407A4 (en) 2015-06-03
IL259889A (en) 2018-07-31
US10358452B2 (en) 2019-07-23
US20150065536A1 (en) 2015-03-05
US9549923B2 (en) 2017-01-24
KR20190042115A (ko) 2019-04-23
MY153046A (en) 2014-12-31
CO6480991A2 (es) 2012-07-16
IL217096A (en) 2015-06-30
US20110002990A1 (en) 2011-01-06
US20180177883A1 (en) 2018-06-28
KR101795330B1 (ko) 2017-11-07
SG177445A1 (en) 2012-02-28
AU2010266205B2 (en) 2013-08-15
ZA201109438B (en) 2013-05-29
US10577376B2 (en) 2020-03-03
US20120142719A1 (en) 2012-06-07
US8759368B2 (en) 2014-06-24
NZ597235A (en) 2013-08-30
CL2011003347A1 (es) 2012-07-13
RU2505541C2 (ru) 2014-01-27
CN102480959B (zh) 2014-05-21
US9872915B2 (en) 2018-01-23
AU2010266205A1 (en) 2012-02-02
US9132125B2 (en) 2015-09-15
UA102916C2 (uk) 2013-08-27
CU24128B1 (es) 2015-09-29
KR101655972B1 (ko) 2016-09-08
CA2766388A1 (en) 2011-01-06
KR101877467B1 (ko) 2018-07-11
CR20110688A (es) 2012-03-22
KR20160106781A (ko) 2016-09-12
ZA201300747B (en) 2014-09-25
BR112012000569B8 (pt) 2021-05-25
KR20120048589A (ko) 2012-05-15
JP5442862B2 (ja) 2014-03-12
US20130259909A1 (en) 2013-10-03
US9650387B2 (en) 2017-05-16
US10654863B2 (en) 2020-05-19
US20180104352A1 (en) 2018-04-19
JP2012532142A (ja) 2012-12-13
US20130245265A1 (en) 2013-09-19
US20170226118A1 (en) 2017-08-10
WO2011002991A1 (en) 2011-01-06
MX2012000128A (es) 2012-04-30
US8748413B2 (en) 2014-06-10
US8828978B2 (en) 2014-09-09
EP3560336A1 (en) 2019-10-30
US8927716B2 (en) 2015-01-06
US20150087667A1 (en) 2015-03-26
US20160200731A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
BR112012000569A2 (pt) ácido benzóico, derivados de ácido benzóico e conjugados de ácido heteroaril carboxílico de hidrocodona, pró-farmacos, métodos de produção e uso destes
HUS2300018I1 (hu) Rákellenes hatású kinoli-8-szulfonamid-származékok
SG11201401856VA (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
DOP2011000086A (es) Derivados de acido 1-amino-2-ciclobutiletilboronico
BRPI1013937A2 (pt) compostos de ácido carboxílico
DK2623507T3 (da) Morpholinonukleinsyrederivat
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI0912420A2 (pt) portal wlan sequenciável
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
EP2413436A4 (en) COAXIAL CONNECTOR DEVICE
BRPI0913368A2 (pt) compostos de ácido carboxílico
DK2397480T3 (da) Diazepindionderivat
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
BRPI1013844A2 (pt) derivados de piridina-isoxazol
EP2448408A4 (en) CONJUGATES OF PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID AND HYDROCODONE PRODRUGS, METHODS OF MAKING AND USING THEM
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BRPI0814251A2 (pt) derivados de ácido heterociclil-carboxílicos heterociclicamente substituídos
BR112012004300A2 (pt) preparação de ácido acético.
DK2387580T3 (da) Deoxyactagardinderivater
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
EP2457898A4 (en) FULLER DERIVATIVE
DK2343201T3 (da) Anhængerkobling
BR112013013837A2 (pt) derivados de substituição de imidazoquinolina
DK2307397T3 (da) 6-substituerede phenoxychroman-carboxylsyrederivater

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF